Related Experiment Video

Updated: May 21, 2026

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
05:14

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography

Published on: August 11, 2023

Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration

Alan F Cruess1, Alan Berger, Kevin Colleaux

  • 1Dalhousie University, Halifax, NS. alan.cruess@dal.ca

Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie
|June 13, 2012
PubMed
Abstract

Insights

Canadian experts developed guidelines for managing wet age-related macular degeneration (AMD). Ranibizumab is recommended, though bevacizumab shows similar efficacy, with safety differences needing further study.

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Medical Consensus

Background:

  • Age-related macular degeneration (AMD) poses a significant threat to vision.
  • Anti-vascular endothelial growth factor (anti-VEGF) therapies offer promising treatments for AMD.
  • Unequal access to advanced eye care persists across Canada.

Framework:

  • A consensus document was developed by ten Canadian retina specialists.
  • The process involved reviewing clinical evidence, current practices, and existing guidelines.
  • Expert discussions aimed to establish optimal management strategies for exudative AMD.

Implementation:

  • The consensus provides practical guidelines for Canadian ophthalmologists and retina specialists.
  • Focuses on the management of patients with neovascular AMD.
  • Addresses treatment strategies in the context of national approvals and policies.

Implications:

  • Ranibizumab is currently the preferred agent for wet AMD due to robust evidence and Health Canada approval.
  • Bevacizumab demonstrates comparable efficacy in visual acuity preservation and improvement.
  • Further research is needed to clarify potential safety differences between ranibizumab and bevacizumab.

More Related Videos

Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration10:14

Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...